Puretech Health(PRTC) - 2024 Q4 - Annual Report

30 April 2025 Exhibit 99.1 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2024 Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity 2, Seaport Therapeutics, which raised over $325 million ...